Original articleScreening for Glaucoma in High-Risk Populations Using Optical Coherence Tomography
Section snippets
Methods
The Standards for Reporting of Diagnostic Accuracy were reviewed and followed.25
Results
All subjects met ≥1 high-risk inclusion criterion. Of 333 participants who were examined, 30 were excluded owing to missing data: 7 subjects had a missing FDT VF and 23 had missing Stratus scans. Of the remaining 303 patients, 51 were examined and tested at the hospital (Rosemont pavilion where the eye clinic was located until 2005), 77 were examined and tested at the new ambulatory eye clinic of the hospital (Centre de santé ambulatoire, which opened in 2005), 127 at the Glaucoma Institute of
Discussion
Glaucoma imaging is currently used as an adjunct to other clinical parameters important in glaucoma diagnosis and progression.33 The performance of the Stratus for glaucoma detection has been evaluated in patients followed in eye clinics. Within this population, the sensitivity of the best performing RNFL parameters ranges between 75% and 85% for specificities >88%.17, 22, 34, 35, 36, 37 However, patients followed in eye clinics by glaucoma specialists have more advanced disease than in a
Acknowledgments
The authors thank Miguel Chagnon, PhD, for his statistical help.
References (50)
- et al.
Prevalence of open-angle glaucoma and ocular hypertension in Latinos: the Los Angeles Latino Eye Study
Ophthalmology
(2004) - et al.
The earliest observable defect in glaucoma?
Lancet
(1972) - et al.
Diagnostic capability of optical coherence tomography (Stratus OCT 3) in early glaucoma
Ophthalmology
(2007) - et al.
Identifying early glaucoma with optical coherence tomography
Am J Ophthalmol
(2004) - et al.
Validity of a new disk grading scale for estimating glaucomatous damage: correlation with visual field damage
Am J Ophthalmol
(2002) - et al.
Validity of screening for glaucomatous optic nerve damage using confocal scanning laser ophthalmoscopy (Heidelberg Retina Tomograph II) in high-risk populations: a pilot study
Ophthalmology
(2005) - et al.
Frequency doubling technology perimetry for detection of glaucomatous visual field loss
Am J Ophthalmol
(2000) - et al.
Mapping the visual field to the optic disc in normal tension glaucoma eyes
Ophthalmology
(2000) - et al.
Optic nerve head and retinal nerve fiber layer analysis: a report by the American Academy of Ophthalmology
Ophthalmology
(2007) - et al.
Evaluation of retinal nerve fiber layer, optic nerve head, and macular thickness measurements for glaucoma detection using optical coherence tomography
Am J Ophthalmol
(2005)
Comparison of three optical coherence tomography scanning areas for detection of glaucomatous damage
Am J Ophthalmol
Short wavelength automated perimetry, frequency doubling technology perimetry, and pattern electroretinography for prediction of progressive glaucomatous standard visual field defects
Ophthalmology
Frequency doubling technology perimetry abnormalities as predictors of glaucomatous visual field loss
Am J Ophthalmol
Prevalence of open-angle glaucoma among adults in the United States
Arch Ophthalmol
The screening of primary open-angle glaucoma
Screening for glaucoma: recommendation statement
Ann Fam Med
Screening for primary open-angle glaucoma in the primary care setting: an update for the US Preventive Services Task Force
Ann Fam Med
Relationship between intraocular pressure and primary open angle glaucoma among white and black Americans: the Baltimore Eye Survey
Arch Ophthalmol
Family history and risk of primary open angle glaucoma: the Baltimore Eye Survey
Arch Ophthalmol
Analyses of reported family history of glaucoma: a preliminary investigation
Ophthalmic Epidemiol
Genetic risk of primary open-angle glaucoma: population-based familial aggregation study
Arch Ophthalmol
Screening for open angle glaucoma: systematic review of cost-effectiveness studies
J Glaucoma
Optic disc parameters and onset of glaucomatous field loss: IMethods and progressive changes in disc morphology
Arch Ophthalmol
Early detection of glaucoma by longitudinal monitoring of the optic disc structure
Graefes Arch Clin Exp Ophthalmol
Features of the optic disc in preglaucomatous eyes
Arch Ophthalmol
Cited by (27)
Posterior pole asymmetry analysis and retinal thickness measurements in young relatives of glaucoma patients
2015, Kaohsiung Journal of Medical SciencesCitation Excerpt :One of our starting points was that it is possible that relatives of glaucoma patients have fewer retinal ganglion cells at the start of their lives and are therefore more likely to display thinner retinal layers. In contrast to previous reports, we included only young adults in order to eliminate age-related glaucoma risk [5,6]. We hypothesized that new early diagnostic techniques may show some defects in the posterior pole retina of young relatives of POAG patients.
Screening for Glaucoma
2015, Glaucoma: Second EditionLikelihood ratios for glaucoma diagnosis using spectral-domain optical coherence tomography
2013, American Journal of OphthalmologyThe value of tests in the diagnosis and management of glaucoma
2011, American Journal of OphthalmologyCitation Excerpt :Thus, appropriate clinical acumen in the application of testing will naturally increase test usefulness. Sophisticated arguments have been made that combinations of tests may improve the performance of any single test in isolation, with the identification of clinically relevant changes after integrating diverse measures (such as computerized perimetry data with HRT or OCT imaging)—but often these efforts show only equivocal sensitivities and specificities.62–71 The few population-based attempts to improve on the detection of glaucoma using this integrative strategy have not been very successful.9
Telemedicine for glaucoma: the state-of-the-art and trends of development
2023, Rossiiskii Oftal'mologicheskii ZhurnalComparison of visual fields and retinal nerve fiber layer thickness in assessing optic nerve head damage in patients with primary open-angle glaucoma
2022, Indian Journal of Clinical and Experimental Ophthalmology
Manuscript no. 2009-300.
Financial Disclosure(s): The authors have made the following disclosures:
Gisèle Li - research funding, consultant/advisor and lecture – Allergan; consultant/advisor and lecture fees – Pfizer; consultant/advisor fees – Alcon; lecture fees - Merck & Co.
Paul Harasymowycz - consultant/advisor and lecture fees - Allergan, Alcon, Pfizer, and Merck & Co; consultant fees - SOLX.
The funding organizations had no role in the design or conduct of this research.
Supported by Fonds de la recherche en santé du Québec and Allergan, Irvine, CA. The funding organization had no role in the design or conduct of this research.